Somatostatin and its analog enhance the formation of human leukocyte migration inhibiting factor: Further evidence for immunomodulatory action of somatostatin
Q3 · MEDICINE
Article
Author: Marek Pawlikowski ; Piotr Zelazowski ; Henryk Stepien ; Andrew V. Schally
The effect of somatostatin-14 (SST) and somatostatin analog D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH2 (RC-102) on migration inhibition of human leukocytes induced by cardiac antigen or phytohemagglutinin (PHA) was investigated. Both SST and RC-102 augmented the migration inhibition, thus indicating the enhanced formation or action of the leukocyte migration inhibiting factor (LMIF). This finding provides additional evidence for the immunomodulatory action of somatostatin.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.